Information Provided By: 
Fly News Breaks for January 7, 2019
EXAS
Jan 7, 2019 | 08:17 EDT
Canaccord analyst Mark Massaro noted Exact Sciences delivered upside to Q4 Street estimates, "easily" beating on the top-line. Its volume growth was its largest sequential quarterly growth in six quarters and its roughly 15,000 new ordering providers was the largest quarterly addition of ordering clinicians in the company's history, said Massaro, who reiterated his Buy rating and $87 price target on Exact Sciences shares.
News For EXAS From the Last 2 Days
There are no results for your query EXAS
